Drug‐releasing intravesical floating technology for sequential gemcitabine and docetaxel in non‐muscle‐invasive bladder cancer
The DRIFT enables controlled sequential delivery of Gem/Doce, reliably maintaining docetaxel containment for up to 120 min during gemcitabine pre-treatment. Future in vivo validation will establish safety and therapeutic potential. This platform has broader applications beyond NMIBC, including urinary tract infections and interstitial cystitis.
Authors
- Melinda Z. Fu (ORCID: https://orcid.org/0000-0002-6853-5445)
- Michael A. O’Donnell (ORCID: https://orcid.org/0000-0001-7202-6427)
- Kyle R. Balk
- Jianling Bi
- Ikenna Nwosu
- Emily Witt
- Ashley C. Rhodes
- César P. Reis (ORCID: https://orcid.org/0000-0001-8481-8587)
- Ian Sutton
- Vignesh T. Packiam (ORCID: https://orcid.org/0000-0001-8397-7797)
- James D. Byrne (ORCID: https://orcid.org/0000-0002-6436-2866)
- Kaitlyn A. McClintic
Institutions
- Rutgers, The State University of New Jersey (US)
- University of Iowa (US)
- Duke University (US)
- Chongqing Maternal and Child Health Hospital (CN)
- Children's Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1111/bju.70060
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- Holden Comprehensive Cancer Center, University of Iowa
- National Cancer Institute